JP7536296B2 - 栄養障害型表皮水疱症治療薬 - Google Patents

栄養障害型表皮水疱症治療薬 Download PDF

Info

Publication number
JP7536296B2
JP7536296B2 JP2020566497A JP2020566497A JP7536296B2 JP 7536296 B2 JP7536296 B2 JP 7536296B2 JP 2020566497 A JP2020566497 A JP 2020566497A JP 2020566497 A JP2020566497 A JP 2020566497A JP 7536296 B2 JP7536296 B2 JP 7536296B2
Authority
JP
Japan
Prior art keywords
cells
composition
acid sequence
mesenchymal stem
epidermolysis bullosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020566497A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020149395A5 (https=
JPWO2020149395A1 (ja
Inventor
克人 玉井
康 菊池
智樹 玉越
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Publication of JPWO2020149395A1 publication Critical patent/JPWO2020149395A1/ja
Publication of JPWO2020149395A5 publication Critical patent/JPWO2020149395A5/ja
Priority to JP2024124327A priority Critical patent/JP7833204B2/ja
Application granted granted Critical
Publication of JP7536296B2 publication Critical patent/JP7536296B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020566497A 2019-01-18 2020-01-17 栄養障害型表皮水疱症治療薬 Active JP7536296B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024124327A JP7833204B2 (ja) 2019-01-18 2024-07-31 栄養障害型表皮水疱症治療薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019007201 2019-01-18
JP2019007201 2019-01-18
PCT/JP2020/001433 WO2020149395A1 (ja) 2019-01-18 2020-01-17 栄養障害型表皮水疱症治療薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024124327A Division JP7833204B2 (ja) 2019-01-18 2024-07-31 栄養障害型表皮水疱症治療薬

Publications (3)

Publication Number Publication Date
JPWO2020149395A1 JPWO2020149395A1 (ja) 2021-11-25
JPWO2020149395A5 JPWO2020149395A5 (https=) 2023-01-26
JP7536296B2 true JP7536296B2 (ja) 2024-08-20

Family

ID=71613343

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566497A Active JP7536296B2 (ja) 2019-01-18 2020-01-17 栄養障害型表皮水疱症治療薬
JP2024124327A Active JP7833204B2 (ja) 2019-01-18 2024-07-31 栄養障害型表皮水疱症治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024124327A Active JP7833204B2 (ja) 2019-01-18 2024-07-31 栄養障害型表皮水疱症治療薬

Country Status (7)

Country Link
US (1) US20220088083A1 (https=)
EP (1) EP3912644A4 (https=)
JP (2) JP7536296B2 (https=)
KR (1) KR20210116531A (https=)
CN (1) CN113646006A (https=)
AU (1) AU2020209687A1 (https=)
WO (1) WO2020149395A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020459825A1 (en) * 2020-07-22 2023-03-16 Osaka University Therapeutic agent for dystrophic epidermolysis bullosa
JP2025094280A (ja) * 2022-01-21 2025-06-25 国立大学法人大阪大学 細胞シート
CN116555349A (zh) * 2023-01-09 2023-08-08 中吉智药(南京)生物技术有限公司 一种腺相关病毒载体及其构建方法与应用
CN118001404B (zh) * 2024-02-06 2025-02-25 四川大学华西医院 抑制C17orf67基因表达试剂在制备治疗获得性大疱表皮松解症药物中的用途
KR102736437B1 (ko) * 2024-06-20 2024-12-02 주식회사 에이바이오테크 콜라겐 합성 촉진 활성을 갖는 콜라겐 타입 7 저분자 펩타이드 및 이를 이용한 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161180A1 (en) 2016-03-18 2017-09-21 Intrexon Corporation Compositions and methods for treatment of type vii collagen deficiencies
US20180142262A1 (en) 2016-11-22 2018-05-24 Regents Of The University Of Minnesota Method for correcting a genetic sequence
WO2018213502A1 (en) 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2720903C (en) * 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
AU2013259647B2 (en) * 2012-05-07 2018-11-08 Corteva Agriscience Llc Methods and compositions for nuclease-mediated targeted integration of transgenes
US12558316B2 (en) * 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
CN105683376A (zh) * 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
WO2017035416A2 (en) * 2015-08-25 2017-03-02 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
JP7159048B2 (ja) 2016-01-04 2022-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 遺伝子修正自己ケラチノサイトを使用する劣性栄養障害型表皮水疱症のための遺伝子療法
RS60410B1 (sr) * 2016-04-08 2020-07-31 Krystal Biotech Inc Kompozicije za upotrebu u metodama za tretman rana, poremećaja i bolesti kože
WO2018007871A1 (en) * 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
WO2018154413A1 (en) * 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders
US20200038486A1 (en) * 2017-04-07 2020-02-06 StemRIM Inc. Therapeutic medicine for fibrous disease
WO2018235834A1 (ja) * 2017-06-19 2018-12-27 国立大学法人北海道大学 表皮水疱症の治療剤
JP2019007201A (ja) 2017-06-23 2019-01-17 システム計測株式会社 免震構造
CN107904208B (zh) * 2017-12-25 2019-11-01 云舟生物科技（广州）有限公司 细胞表型研究用的细胞克隆及其筛选方法和应用
AU2019261438B2 (en) * 2018-04-27 2024-08-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of FOXP3 in edited CD34+ cells
JP2022532078A (ja) * 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ 皮膚及び創傷のための組成物並びにその使用の方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161180A1 (en) 2016-03-18 2017-09-21 Intrexon Corporation Compositions and methods for treatment of type vii collagen deficiencies
US20180142262A1 (en) 2016-11-22 2018-05-24 Regents Of The University Of Minnesota Method for correcting a genetic sequence
WO2018213502A1 (en) 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EL-DAROUTI, M., et al.，Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoietic stem cells: a rando，Dermatologic Therapy，2016年，Vol.29，pp.96-100
KUHL, T., et al.，High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in，Mol. Ther.，2015年，Vol.23, No.8，pp.1368-1379，doi: 10.1038/mt.2015.58
玉井 克人，表皮水疱症に対する再生医療と遺伝子治療：現状と展望，医学のあゆみ，2018年05月05日，Vol.265, No.5，pp.463-468

Also Published As

Publication number Publication date
US20220088083A1 (en) 2022-03-24
EP3912644A4 (en) 2022-09-28
AU2020209687A1 (en) 2021-07-29
JP2024153826A (ja) 2024-10-29
JP7833204B2 (ja) 2026-03-19
WO2020149395A1 (ja) 2020-07-23
JPWO2020149395A1 (ja) 2021-11-25
KR20210116531A (ko) 2021-09-27
CN113646006A (zh) 2021-11-12
EP3912644A1 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
JP7536296B2 (ja) 栄養障害型表皮水疱症治療薬
JP7158427B2 (ja) ヘモグロビン異常症を処置するためのグロビン遺伝子療法
JP7233375B2 (ja) リソソーム障害を治療する方法
JP2019536782A (ja) ＣＲＩＳＰＲ／Ｃｐｆ１媒介性遺伝子編集による筋ジストロフィーの予防
JP7228523B2 (ja) ヘモグロビン異常症を治療するためのベクターおよび組成物
Al-Allaf et al. LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives
CN112673094B (zh) 病毒载体产生
JP7633155B2 (ja) 人工トランス活性化因子による選択
JP2025519070A (ja) 効率的ｉｎ ｖｉｖｏ送達のための組成物および方法
EA024878B1 (ru) Ген, кодирующий мутантную глюкокиназу человека, отличающуюся увеличенной стабильностью, и его применение для контроля глюкозы в крови или предупреждения и лечения нарушений углеводного обмена
JP2026027332A (ja) 栄養障害型表皮水疱症の治療薬
JP7710265B2 (ja) 酸化ストレス抵抗性を有する間葉系幹細胞、この製造方法および用途
KR20200010379A (ko) 안지오포이에틴-1 또는 vegf를 분비하는 줄기세포 및 이를 포함하는 심혈관 질환의 예방 또는 치료용 약학 조성물
CN113544279A (zh) 包含芳基硫酸酯酶a的重组载体及其在用于治疗异染性脑白质营养不良的干细胞治疗中的用途
US20260098062A1 (en) Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
JP2021522278A (ja) ライソゾーム病を改善するための、レンチウイルスベクターが形質導入されたｔ−ｒａｐａ細胞の使用
JP2025506976A (ja) 低免疫原性幹細胞、幹細胞から分化または由来した低免疫原性細胞およびこの製造方法
EP4467646A1 (en) Cell sheet
WO2026090544A1 (en) Gene silencing
HK40108790A (zh) 具有氧化应激抗性的间充质干细胞、其制备方法及用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240731

R150 Certificate of patent or registration of utility model

Ref document number: 7536296

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150